Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 36 Neoplasms 8 Lung Neoplasms 7 Neoplasm Metastasis 4 Neoplasms by Site 3 Lymphoma, Large-Cell, Anaplastic 3 Hematologic Neoplasms 3 Breast Neoplasms 3 Brain Neoplasms 3 Thyroid Neoplasms 2 Sarcoma 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms by Histologic Type 2 Lymphoproliferative Disorders 2 Gastrointestinal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Urinary Bladder Neoplasms 1 Thyroid Cancer, Papillary 1 Thoracic Neoplasms 1 Solid Tumors 1 Sexual Dysfunction, Physiological 1 Salivary Gland Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Rare Tumour 1 Rare Tumor 1 Prostatic Neoplasms 1 Neuroendocrine Tumors 1

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

ALK+ Advanced NSCLC × alectinib × Clear all

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡